However, huge news came out regarding one of the companys experimental drugs, causing shares to spike by over 14%
Funding The authors on this manuscript were supported, in part, by grants from the NIH [ RO1 CA210637, RO1CA206444, and RO1 CA183459, UO1 CA200466, P50 CA127297 and PO1 CA217798]
Blood (2022) 139(23):340217
DeShields says there can be additional barriers blocking patients access, including prior authorization requirements, restrictive use criteria, and substantial out-of-pocket costs. Of these, he says, affordability remains the largest obstacle to successful implementation in everyday medical practice. What are Aetnas coverage requirements for Wegovy